Verrica Pharmaceuticals to Announce Q1 2024 Financial Results and Corporate Update on May 13, 2024

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), specializing in dermatology therapeutics, has announced a conference call and live webcast scheduled for 8:30 a.m. ET on Monday, May 13, 2024. The session aims to deliver a corporate update and review the company's financial performance for the first quarter ending on March 31, 2024. Interested participants can join the call by dialing specific numbers for domestic and international access and using the provided conference ID. The live audio webcast will be available on the company's website, with a replay accessible for 90 days post-event.

Verrica Pharmaceuticals Inc. is dedicated to developing treatments for skin diseases that require medical interventions. The company's notable milestone occurred on July 21, 2023, when the FDA approved its lead product, YCANTH™ (cantharidin), to treat molluscum contagiosum. This viral skin infection, which predominantly affects children, impacts around 6 million individuals in the United States. YCANTH™ thus became the first FDA-approved treatment for this condition in both pediatric and adult patients.

Beyond molluscum contagiosum, Verrica is advancing the development of VP-102 for the treatment of common and external genital warts. These conditions represent significant unmet needs in dermatology. In addition, Verrica is working on VP-103, another cantharidin-based product aimed at treating plantar warts.

Furthermore, Verrica is expanding its portfolio through a licensing agreement with Lytix Biopharma AS. This collaboration focuses on developing and commercializing VP-315 (formerly known as LTX-315 and VP-LTX-315) for dermatologic oncology conditions, potentially broadening the therapeutic scope of Verrica's offerings.